‘Management Dispute’ Fully Resolved, First Regular Shareholders’ Meeting
Chairperson Song Young-sook Steps Down, Vice Chairpersons Lim Ju-hyun and Kim Jae-gyo Appointed
Focus on Performance-Driven Business..”Maximizing Shareholder Value”
Park Jae-hyun, CEO of Hanmi Pharmaceutical, speaking at the 15th regular shareholders’ meeting held at the Hanmi Pharmaceutical headquarters in Bangi-dong, Songpa-gu, Seoul on the 26th. Provided by Hanmi Pharmaceutical
, “[Financial News] The Hanmi Pharmaceutical Group, having completely resolved its management dispute, is announcing its leap towards ‘New Hanmi’ as it begins to expand its competitiveness in both domestic and international markets. “,
, ‘For this, Hanmi Group plans to place proven experts in key management positions and focus on maximizing shareholder value by linking management performance with stock prices. ‘,
, ‘On the 26th, Hanmi Pharmaceutical and Hanmi Science consecutively held regular shareholders’ meetings at 8:30 AM and 10 AM to reveal their blueprint for the group’s future growth strategy. ‘,
, ‘The Hanmi Group has experienced a severe management dispute over the past year. Song Young-sook, the chairperson and spouse of the late founder Im Sung-ki, alongside her daughter Lim Ju-hyun, the vice chairperson of Hanmi Science, faced off against her sons, Im Jong-yoon and Im Jong-hoon, over control, and ultimately, the mother and daughter emerged victorious. ‘,
, ‘This shareholder meeting is significant as it is the first held after resolving the management dispute, and it presented the new management system and direction the group will take. ‘,
, ‘Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated during the shareholders’ meeting, “Hanmi Pharmaceutical recorded the highest sales ever last year, achieving an operating profit exceeding 200 billion KRW, the highest in the industry.” He added, “Moreover, we have over 20 blockbuster drugs with sales of more than 10 billion KRW each and achieved the distinction of being the number one outpatient prescription seller for seven consecutive years.” ‘,
, ‘Park further mentioned, “However, management outcomes should reflect in the stock price, and pondering over the current stock price burdens my heart,” emphasizing his commitment to enhancing shareholder value. Hanmi Pharmaceutical plans to focus on its strength in R&D, aiming to elevate business performance through tangible new drug developments like obesity treatments. ‘,
, ‘He declared, “We will once again engrain the spirit of creativity, challenge, and innovation that defines Hanmi, ensuring that Hanmi can undertake unique business ventures to reward shareholders with results. By this time next year, I hope to express gratitude to shareholders with a more comfortable face.” ‘,
, ‘At Hanmi Pharmaceutical’s shareholders’ meeting, the motion to appoint Choi In-young, the head of the R&D center, and Kim Jae-gyo, recently appointed vice chairperson and former vice president of Meritz Securities, as internal directors was passed. ‘,
, “Choi, selected as an internal director, has been involved in new drug development with Hanmi for over 20 years and has led global technology exports, known as an ‘R&D expert.’ He aims to continue Hanmi’s R&D success, secure future growth engines, and contribute to developing new modalities. “,
, ‘During the subsequent shareholders’ meeting of the holding company Hanmi Science, decisions regarding the innovation of New Hanmi’s management system continued. Chairperson Song Young-sook, who could not attend the meeting due to personal reasons, relinquished her CEO position, while the proposal to appoint Vice Chairpersons Lim Ju-hyun and Kim Jae-gyo as internal directors was approved. ‘,
, ‘Notably, Vice Chairperson Kim will oversee the management of Hanmi Science, the holding company, alongside owner Vice Chairperson Lim. ‘,
, “Vice Chairperson Lim has led Hanmi’s Global Business Division, R&D Center, and Management Division and has previously held the position of Chief Strategy Officer for the group. She has demonstrated her expertise in R&D, notably achieving results in the ‘H.O.P’ project for developing obesity treatments at Hanmi. “,
, ‘Vice Chairperson Kim began his career at Yuhan Corporation, worked there for nearly 30 years, and in 2021 moved to Meritz Securities, where he served as vice president. He is known as an expert with comprehensive experience in pharmaceutical management, technology exports, and investments. \n’]